Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women
Copyright © 2019 Massachusetts Medical Society..
BACKGROUND: The safety, efficacy, and appropriate timing of isoniazid therapy to prevent tuberculosis in pregnant women with human immunodeficiency virus (HIV) infection who are receiving antiretroviral therapy are unknown.
METHODS: In this multicenter, double-blind, placebo-controlled, noninferiority trial, we randomly assigned pregnant women with HIV infection to receive isoniazid preventive therapy for 28 weeks, initiated either during pregnancy (immediate group) or at week 12 after delivery (deferred group). Mothers and infants were followed through week 48 after delivery. The primary outcome was a composite of treatment-related maternal adverse events of grade 3 or higher or permanent discontinuation of the trial regimen because of toxic effects. The noninferiority margin was an upper boundary of the 95% confidence interval for the between-group difference in the rate of the primary outcome of less than 5 events per 100 person-years.
RESULTS: A total of 956 women were enrolled. A primary outcome event occurred in 72 of 477 women (15.1%) in the immediate group and in 73 of 479 (15.2%) in the deferred group (incidence rate, 15.03 and 14.93 events per 100 person-years, respectively; rate difference, 0.10; 95% confidence interval [CI], -4.77 to 4.98, which met the criterion for noninferiority). Two women in the immediate group and 4 women in the deferred group died (incidence rate, 0.40 and 0.78 per 100 person-years, respectively; rate difference, -0.39; 95% CI, -1.33 to 0.56); all deaths occurred during the postpartum period, and 4 were from liver failure (2 of the women who died from liver failure had received isoniazid [1 in each group]). Tuberculosis developed in 6 women (3 in each group); the incidence rate was 0.60 per 100 person-years in the immediate group and 0.59 per 100 person-years in the deferred group (rate difference, 0.01; 95% CI, -0.94 to 0.96). There was a higher incidence in the immediate group than in the deferred group of an event included in the composite adverse pregnancy outcome (stillbirth or spontaneous abortion, low birth weight in an infant, preterm delivery, or congenital anomalies in an infant) (23.6% vs. 17.0%; difference, 6.7 percentage points; 95% CI, 0.8 to 11.9).
CONCLUSIONS: The risks associated with initiation of isoniazid preventive therapy during pregnancy appeared to be greater than those associated with initiation of therapy during the postpartum period. (Funded by the National Institutes of Health; IMPAACT P1078 TB APPRISE ClinicalTrials.gov number, NCT01494038.).
| Errataetall: |
CommentIn: N Engl J Med. 2020 Mar 19;382(12):1184. - PMID 32187482 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:381 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 381(2019), 14 vom: 03. Okt., Seite 1333-1346 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gupta, Amita [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antitubercular Agents |
|---|
| Anmerkungen: |
Date Completed 23.10.2019 Date Revised 29.03.2024 published: Print ClinicalTrials.gov: NCT01494038 CommentIn: N Engl J Med. 2020 Mar 19;382(12):1184. - PMID 32187482 Citation Status MEDLINE |
|---|
| doi: |
10.1056/NEJMoa1813060 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM301851921 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM301851921 | ||
| 003 | DE-627 | ||
| 005 | 20240329232238.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa1813060 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1354.xml |
| 035 | |a (DE-627)NLM301851921 | ||
| 035 | |a (NLM)31577875 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gupta, Amita |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2019 | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT01494038 | ||
| 500 | |a CommentIn: N Engl J Med. 2020 Mar 19;382(12):1184. - PMID 32187482 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Massachusetts Medical Society. | ||
| 520 | |a BACKGROUND: The safety, efficacy, and appropriate timing of isoniazid therapy to prevent tuberculosis in pregnant women with human immunodeficiency virus (HIV) infection who are receiving antiretroviral therapy are unknown | ||
| 520 | |a METHODS: In this multicenter, double-blind, placebo-controlled, noninferiority trial, we randomly assigned pregnant women with HIV infection to receive isoniazid preventive therapy for 28 weeks, initiated either during pregnancy (immediate group) or at week 12 after delivery (deferred group). Mothers and infants were followed through week 48 after delivery. The primary outcome was a composite of treatment-related maternal adverse events of grade 3 or higher or permanent discontinuation of the trial regimen because of toxic effects. The noninferiority margin was an upper boundary of the 95% confidence interval for the between-group difference in the rate of the primary outcome of less than 5 events per 100 person-years | ||
| 520 | |a RESULTS: A total of 956 women were enrolled. A primary outcome event occurred in 72 of 477 women (15.1%) in the immediate group and in 73 of 479 (15.2%) in the deferred group (incidence rate, 15.03 and 14.93 events per 100 person-years, respectively; rate difference, 0.10; 95% confidence interval [CI], -4.77 to 4.98, which met the criterion for noninferiority). Two women in the immediate group and 4 women in the deferred group died (incidence rate, 0.40 and 0.78 per 100 person-years, respectively; rate difference, -0.39; 95% CI, -1.33 to 0.56); all deaths occurred during the postpartum period, and 4 were from liver failure (2 of the women who died from liver failure had received isoniazid [1 in each group]). Tuberculosis developed in 6 women (3 in each group); the incidence rate was 0.60 per 100 person-years in the immediate group and 0.59 per 100 person-years in the deferred group (rate difference, 0.01; 95% CI, -0.94 to 0.96). There was a higher incidence in the immediate group than in the deferred group of an event included in the composite adverse pregnancy outcome (stillbirth or spontaneous abortion, low birth weight in an infant, preterm delivery, or congenital anomalies in an infant) (23.6% vs. 17.0%; difference, 6.7 percentage points; 95% CI, 0.8 to 11.9) | ||
| 520 | |a CONCLUSIONS: The risks associated with initiation of isoniazid preventive therapy during pregnancy appeared to be greater than those associated with initiation of therapy during the postpartum period. (Funded by the National Institutes of Health; IMPAACT P1078 TB APPRISE ClinicalTrials.gov number, NCT01494038.) | ||
| 650 | 4 | |a Equivalence Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 7 | |a Antitubercular Agents |2 NLM | |
| 650 | 7 | |a Isoniazid |2 NLM | |
| 650 | 7 | |a V83O1VOZ8L |2 NLM | |
| 700 | 1 | |a Montepiedra, Grace |e verfasserin |4 aut | |
| 700 | 1 | |a Aaron, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Theron, Gerhard |e verfasserin |4 aut | |
| 700 | 1 | |a McCarthy, Katie |e verfasserin |4 aut | |
| 700 | 1 | |a Bradford, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Chipato, Tsungai |e verfasserin |4 aut | |
| 700 | 1 | |a Vhembo, Tichaona |e verfasserin |4 aut | |
| 700 | 1 | |a Stranix-Chibanda, Lynda |e verfasserin |4 aut | |
| 700 | 1 | |a Onyango-Makumbi, Carolyne |e verfasserin |4 aut | |
| 700 | 1 | |a Masheto, Gaerolwe R |e verfasserin |4 aut | |
| 700 | 1 | |a Violari, Avy |e verfasserin |4 aut | |
| 700 | 1 | |a Mmbaga, Blandina T |e verfasserin |4 aut | |
| 700 | 1 | |a Aurpibul, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Bhosale, Ramesh |e verfasserin |4 aut | |
| 700 | 1 | |a Mave, Vidya |e verfasserin |4 aut | |
| 700 | 1 | |a Rouzier, Vanessa |e verfasserin |4 aut | |
| 700 | 1 | |a Hesseling, Anneke |e verfasserin |4 aut | |
| 700 | 1 | |a Shin, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Zimmer, Bonnie |e verfasserin |4 aut | |
| 700 | 1 | |a Costello, Diane |e verfasserin |4 aut | |
| 700 | 1 | |a Sterling, Timothy R |e verfasserin |4 aut | |
| 700 | 1 | |a Chakhtoura, Nahida |e verfasserin |4 aut | |
| 700 | 1 | |a Jean-Philippe, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Weinberg, Adriana |e verfasserin |4 aut | |
| 700 | 0 | |a IMPAACT P1078 TB APPRISE Study Team |e verfasserin |4 aut | |
| 700 | 1 | |a Saloojee, Haroon |e investigator |4 oth | |
| 700 | 1 | |a El-Sadr, Wafaa |e investigator |4 oth | |
| 700 | 1 | |a Harrington, David |e investigator |4 oth | |
| 700 | 1 | |a Levine, Jonathan B |e investigator |4 oth | |
| 700 | 1 | |a Lombard, Carl Jacobus |e investigator |4 oth | |
| 700 | 1 | |a Marshall, Mary Faith |e investigator |4 oth | |
| 700 | 1 | |a Mokgatlhe, Lucky |e investigator |4 oth | |
| 700 | 1 | |a Munderi, Paula |e investigator |4 oth | |
| 700 | 1 | |a Nunn, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Singh, Jerome Amir |e investigator |4 oth | |
| 700 | 1 | |a Kwagala, Betty |e investigator |4 oth | |
| 700 | 1 | |a Lombard, Carl Jacobus |e investigator |4 oth | |
| 700 | 1 | |a Mwinga, Alwyn |e investigator |4 oth | |
| 700 | 1 | |a Sow, Papa Salif |e investigator |4 oth | |
| 700 | 1 | |a Hill, Catherine |e investigator |4 oth | |
| 700 | 1 | |a Ellner, Jerrold J |e investigator |4 oth | |
| 700 | 1 | |a John-Stewart, Grace |e investigator |4 oth | |
| 700 | 1 | |a Joffe, Steven |e investigator |4 oth | |
| 700 | 1 | |a Murray, Barbara E |e investigator |4 oth | |
| 700 | 1 | |a Robb, Merlin L |e investigator |4 oth | |
| 700 | 1 | |a Kabugho, Enid |e investigator |4 oth | |
| 700 | 1 | |a Wabwire, Deo |e investigator |4 oth | |
| 700 | 1 | |a Kaganzi, Hellen |e investigator |4 oth | |
| 700 | 1 | |a Maena, Joel |e investigator |4 oth | |
| 700 | 1 | |a Kataike, Hajira |e investigator |4 oth | |
| 700 | 1 | |a Mandima, Patricia |e investigator |4 oth | |
| 700 | 1 | |a Marote, Emmie |e investigator |4 oth | |
| 700 | 1 | |a Mutambanengwe, Mercy |e investigator |4 oth | |
| 700 | 1 | |a Nematadzira, Teacler |e investigator |4 oth | |
| 700 | 1 | |a Maonera, Suzen |e investigator |4 oth | |
| 700 | 1 | |a Chanaiwa, Vongai |e investigator |4 oth | |
| 700 | 1 | |a Mbengeranwa, Tapiwa |e investigator |4 oth | |
| 700 | 1 | |a Maturure, Sukunena |e investigator |4 oth | |
| 700 | 1 | |a Mhembere, Tsungai |e investigator |4 oth | |
| 700 | 1 | |a Nyati, Mandisa |e investigator |4 oth | |
| 700 | 1 | |a Abrahams, Nasreen |e investigator |4 oth | |
| 700 | 1 | |a Cassim, Haseena |e investigator |4 oth | |
| 700 | 1 | |a Mathiba, Ruth |e investigator |4 oth | |
| 700 | 1 | |a Coetzee, Joan |e investigator |4 oth | |
| 700 | 1 | |a Louw, Jeanne |e investigator |4 oth | |
| 700 | 1 | |a Smuts, Marlize |e investigator |4 oth | |
| 700 | 1 | |a Rossouw, Lindie |e investigator |4 oth | |
| 700 | 1 | |a Rossouw, Magdel |e investigator |4 oth | |
| 700 | 1 | |a de Vaal, Celeste |e investigator |4 oth | |
| 700 | 1 | |a Mbaba, Sharon |e investigator |4 oth | |
| 700 | 1 | |a du Preez, Karen |e investigator |4 oth | |
| 700 | 1 | |a Verheye-Dua, Frieda |e investigator |4 oth | |
| 700 | 1 | |a Shao, Aisa |e investigator |4 oth | |
| 700 | 1 | |a Njau, Boniface |e investigator |4 oth | |
| 700 | 1 | |a Sakasaka, Philoteus |e investigator |4 oth | |
| 700 | 1 | |a Semvua, Seleman |e investigator |4 oth | |
| 700 | 1 | |a Kakhu, Tebogo J |e investigator |4 oth | |
| 700 | 1 | |a Ralegoreng, Thuto |e investigator |4 oth | |
| 700 | 1 | |a Omoz-Oarhe, Ayotunde |e investigator |4 oth | |
| 700 | 1 | |a Chakalisa, Unoda |e investigator |4 oth | |
| 700 | 1 | |a Suryavanshi, Nishi |e investigator |4 oth | |
| 700 | 1 | |a Patil, Sandesh |e investigator |4 oth | |
| 700 | 1 | |a Nevrekar, Neetal |e investigator |4 oth | |
| 700 | 1 | |a Bharadwaj, Renu |e investigator |4 oth | |
| 700 | 1 | |a Kulkarni, Vandana |e investigator |4 oth | |
| 700 | 1 | |a Tongprasert, Fuanglada |e investigator |4 oth | |
| 700 | 1 | |a Sudjaritruk, Tavitiya |e investigator |4 oth | |
| 700 | 1 | |a Khamrong, Chintana |e investigator |4 oth | |
| 700 | 1 | |a Janjing, Prapaporn |e investigator |4 oth | |
| 700 | 1 | |a Pierre, Marie Flore |e investigator |4 oth | |
| 700 | 1 | |a Aristhomene, Maria Linda |e investigator |4 oth | |
| 700 | 1 | |a Lespinasse, Dominique |e investigator |4 oth | |
| 700 | 1 | |a Dumont, Emelyne |e investigator |4 oth | |
| 700 | 1 | |a LeBlanc, Rebecca |e investigator |4 oth | |
| 700 | 1 | |a Loftis, Amy James |e investigator |4 oth | |
| 700 | 1 | |a Kim, Soyeon |e investigator |4 oth | |
| 700 | 1 | |a Shapiro, David |e investigator |4 oth | |
| 700 | 1 | |a Tierney, Camlin |e investigator |4 oth | |
| 700 | 1 | |a Rexroad, Vivian |e investigator |4 oth | |
| 700 | 1 | |a Browning, Renee |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d 1945 |g 381(2019), 14 vom: 03. Okt., Seite 1333-1346 |w (DE-627)NLM000008184 |x 1533-4406 |7 nnns |
| 773 | 1 | 8 | |g volume:381 |g year:2019 |g number:14 |g day:03 |g month:10 |g pages:1333-1346 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMoa1813060 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 381 |j 2019 |e 14 |b 03 |c 10 |h 1333-1346 | ||